Op-T’s goals are to provide improved health by maintaining the optimal function of T cells. Normal levels of T cells are important to good health. When T cells become out of control, diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, cardiovascular disease, and sepsis can occur.
We identified a specific type of T cell called TH40 that loses regulation and becomes expanded in a number of diseases. Elevated numbers of TH40 cells have consistently been shown to lead to and sustain the auto-inflammation found in virtually all autoimmune disorders.
Op-T’s proprietary drug has been proven in various pre-clinical tests in animals to restore T cell levels to their normal range and reduce complications from excessive levels of inflammation. With the regulation of this sub-set of T-Cells, we have been able to reverse diabetes in some early-stage mouse models while in other models, the drug has proven therapeutic in controlling glucose, reducing insulin requirements, and reducing complications in Diabetes Mellitus in dogs.
In human clinical trials, we have completed a Phase I study and are currently on track to complete a Phase I clinical trial by the end of 2023. In Phase I and thus far in the Phase Ib studies, the therapeutic has proven safe for use at varied dosage levels.